1. What Comes Second?

2. Progressive Nature of T2D

3. Review of Second-Line Therapy

4. Consider Drug-Specific Effects

5. AACE/ACE Recommendations

6. SUs and DPP-4 Inhibitors

7. Consider Key Characteristics of Antidiabetic Medications

8. Glycemic Durability

9. New Data Examining Long-Term Efficacy for Second-Line T2D

10. Greater Durability With DPP-4 Inhibitors vs SUs

11. Less Hypoglycemia Risk With DPP-4 Inhibitors

12. Clinical Inertia

13. HbA1c and Beta-Cell Preservation

14. Rationale for Better Long-Term Control

15. Closing Comments

16. Abbreviations

17. Abbreviations (cont)